Table 2.
Summary of Age and Doses used in clinical trials by type of therapy(mg/kg)
| Treatment group | Median age, years (range) | Dose(mg/kg) at Initiation of therapy (mean ± SD) | Total dose over first 12 hours (mg/kg) (mean ± SD) | Total dose over first 24 hours (mg/kg) (mean ± SD) |
| Artemether ir*, single dose | 2.08 (0.42 – 5) | 6.7 ± 1.19 | 6.7 ± 1.19 | 6.7 ± 1.19 |
| Artemisinin ir, single dose | 19 (4 – 41) | 20.0 ± 0 | 20.0 ± 0 | 20.0 ± 0 |
| Artemisinin ir, multiple dose | 20 (0.7 – 62) | 31.5 ± 8 | 45.1 ± 14 | 45.1 ± 14 |
| Artesunate ir, multiple dose | 19 (1.3 – 80) | 6.65 ± 4 | 8.1 ± 4.17 | 14.8 ± 7.64 |
| Artesunate ir, single dose – 10 mg/kg | 12 (1.33 – 58) | 9.4 ± 2.47 | 9.4 ± 2.47 | 9.4 ± 2.53 |
| Artesunate per os | 6 (0.92 – 15) | 4.0 ± 0 | 4.0 ± 0 | 4.0 ± 0 |
| Artemisinins parenteral | 18 (0.5 – 66) | 2.94 ± 0.61 | 2.94 ± .0.6 | 3.43 ± 0.99 |
| Quinine parenteral | 3 (0.3 – 49) | 17.6 ± 4.31 | 24.2 ± 4.96 | 36.6 ± 5.7 |
| Quinine parenteral + Artesunate ir | 45 (32 – 60) | - | - | - |
| Artesunate ir, single – 20 mg/kg | 6.3 (2 – 30) | 19.4 ± 1.63 | 19.4 ± 1.63 | 20.7 ± 0.99 |
* ir: Intra-rectal